12,372 trials
Endometriosis
Primary: Percentage of Responders at Month 3 Based on Daily Assessment of Dysmenorrhea (DYS) — 19.6; 46.4; 75.8 percentage of participants — p=< 0.001
Acellular Pertussis · Diphtheria · Tetanus
Primary: Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Toxoid Antigens — 677; 614; 93; 79 Participants
Post-operative Pain
Primary: Change From Baseline in Area Under the Curve (AUC) of Pain Intensity and Relief Scores (SPRID) — 2.68; 3.30; 2.62; 1.93 units on a scale*hour — p=<0.0001
Depressive Disorder · Depression · Depressive Disorder, Major
Primary: Adverse Events (AEs) - All Participants — 400; 511; 1165; 51 Participants
Whole Cell Pertussis · Haemophilus Influenzae Type b · Hepatitis B
Primary: Percentage of Subjects With Meningococcal C Serum Bactericidal Assay (SBA-MenC) Antibody Titers Above the Cut-off Value — 100; 100 Percentage
Fibromyalgia
Primary: Double-Blind Phase: Time to Loss of Therapeutic Response (LTR) — 58; 23 Days — p=0.0186
Candidemia
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 17; 19; 30; 7 Participants
Immunodeficiency Virus Type 1, Human
Primary: Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Less Than (<) 50 Copies Per Milliliter (Copies Per mL) (Virologic Response)…
Crohn's Disease
Primary: Part A: Percentage of Participants Achieving Endoscopic Remission at Week 26 — 11.9 percentage of participants
Perennial Allergic Rhinitis
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs). — 203; 41; 54 participants
Asthma · Elevated Blood Eosinophils · Oral Corticosteroid Dependence
Primary: Number of Participants With Reduction In Daily Oral Corticosteroid (OCS) Dose During Weeks 20-24 As Compared to the Optimized Dose At Baseline — 20; 18; 4; 8…
Spinal Anesthesia · Epidural; Anesthesia
Primary: Time Until PACU Discharge in Minutes — 135; 50 minutes
Diabetes · Diabetes Mellitus, Type 2
Primary: Number of Treatment Emergent Adverse Events (TEAEs) — 228; 197; 186 Number of events
Primary Immune Deficiency Disorders · Common Variable Immunodeficiency · X-linked Agammaglobulinaemia
Primary: Data (Derived From Absolute Concentration) Were Pooled With Historical Data and a Treatment Variable Defined (Subgam-VF or Gammaplex 5% IGIV). Outcome Measure Defined as…
Kidney Cancer
Primary: Disease-free Survival — 192; 197 Participants — p=0.737